StockNews.AI
CTKB
StockNews.AI
187 days

Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

1. Cytek will report Q4 and 2024 results on Feb 27, 2025. 2. Management will discuss business developments during the webcast. 3. Cytek's FSP technology enhances precision in cell analysis. 4. The webcast will be available on Cytek's investor website. 5. Cytek's products are primarily for research, with limited clinical options.

Earnings
+0.19%Current Return
VS
0%S&P 500
$5.2202/13 04:08 PM EDTEvent Start
$5.2302/14 10:45 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings report may not significantly deviate from expectations.

How important is it?

Earnings report impacts investor sentiment, although not likely to be drastic.

Why Short Term?

Market reactions to quarterly results are typically short-lived.

Related Companies

CTKB
February 13, 2025 16:05 ET  | Source: Cytek Biosciences, Inc. FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com About Cytek BiosciencesCytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™ and Northern Lights™ systems and the Cytek Aurora CS cell sorter; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com. Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Enhanced Small Particle, ESP, Amnis and Guava are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@lages.com Investor Contact:Paul D. GoodsonHead of Investor Relationspgoodson@cytekbio.com

Related News